BioAtla
Chemicals & Related Products · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
11085 Torreyana Rd, San Diego, Californi...Phone Number
(858) 558-0708Website
www.bioatla.comRevenue
<$5 MillionStock Symbol
BCABIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
3
1
1
1
1
About BioAtla
BioAtla© is a San Diego biotech company that develops novel monoclonal antibody and cell based therapeutics using our proprietary Conditionally Active Biologics (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!) platforms. These and other proprietary technologies (protected by more than 700 issued patents and patent applications) allow us to develop novel biologics (CABs) that are better drugs in multiple ways including more selective targeting of cancer tissue and improved manufacturability. Improved selectivity for the tumor microenvironment (TME), even when the target is also found in normal tissue, not only may improve safety and thus therapeutic index but also expands the universe of potential drug targets, enabling the possible treatment of previously untreatable cancersExplore more
BioAtla Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is BioAtla your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if BioAtla has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when BioAtla launches new products
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at BioAtla
Check out if BioAtla is spiking on competitors!
Funding: Get notified immidiatlly once BioAtla has new funding data
Click to see if BioAtla had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on BioAtla recently announced quarterly report
BioAtla, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined BioAtla as Masked Content
Find more new buyers
Compare Similar Companies to BioAtla
Compare insights from companies similar to BioAtla, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
BioAtla is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
BioAtla is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about BioAtla.
BioAtla financials insights
Gather financial insights about BioAtla, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Debt
$5.8M
2015
Private Equity
$39M
2016
Series C
$45M
Series B
$84M
2017
Series A
$37M
2020
Multiple Rounds
$261.9M
2021
Share Placement
$75M
BioAtla Tech Stack
A closer look at the technologies used by BioAtla
Most Recent Scoops
Project
Spending/Investment, Product Management, Intellectual Property, Legal Affairs, Pharmaceuticals, Contracts, Finance
Person-Based
Business Finance, Corporate Strategy, Finance, Financing & Debt
Person-Based
Contracts, Mergers
Person-Based
Person-Based
BioAtla News & Media
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202
Context announces buyout of CT-202 future milestones and royalties in exchange for a fully paid-up, non-terminable licenseBioAtla Announces 50-for-1 Share Consolidation - San Diego Today
BioAtla, Inc., a global clinical-stage biotechnology company, announced that it will effect a 50-for-1 share consolidation of its common stock. The consolidation is intended to increase the per-share trading price of the stock and enable the company to regain compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market.BioAtla Announces Share Consolidation
SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ: BCAB or the “Company”), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it will effect a 50-for-1 share consolidation (the “Share Consolidation”) of its common stock, par value $0.0001 per share (the “Common Stock”), that is expected to become effective on April 6, 2026 at 12:01 a.m.BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced its financial results for the full year and fourth quarter ended December 31, 2025 and provided business highlights.
Read more news
Top Chemicals & Related Products Companies
See more top companies
Frequently Asked Questions Regarding BioAtla
Sign Up For FreeTo access detailed company insights
BioAtla© is a San Diego biotech company that develops novel monoclonal antibody and cell based therapeutics using our proprietary Conditionally Active Biologics (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!) platforms. These and other proprietary technologies (protected by more than 700 issued patents and patent applications) allo... Read More
